

**Editorial Series**

**Hepatitis B Vaccine**

Richard A. Garibaldi, M.D.; Bruce H. Hamory, M.D.;  
Peter N.R. Heseltine, M.D.; and  
Edward J. Septimus, M.D., F.A.C.P.

**Original Articles**

**Increasing Occurrence of Methicillin-Resistant  
*Staphylococcus aureus* in the United States**

John M. Boyce, M.D. and William A. Causey, M.D.

**Quantitative Antibiogram as a Potential Tool  
for Epidemiological Typing**

D.J. Flournoy, Ph.D.

**Presumed Autoclave Failure Due to  
False-Positive Spore Strip Tests**

Inge Gurevich, R.N., M.A.; Joyce E. Holmes, M.T.;  
and Burke A. Cunha, M.D.

**Comparison of Broth and Filtration Methods for  
Culturing of Intravenous Fluids**

Jenice N. Longfield, M.D., M.P.H.; Patricia Charache, M.D.;  
Earl L. Diamond, Ph.D.; and Timothy R. Townsend, M.D.

**Recommend Precautions for Patients with  
Legionnaires' Disease**

William R. Jarvis, M.D.

# The Untouchable.



# Introducing Asepti-Catch: Designed to be more patient-proof than any other midstream specimen set.

You know what it's like...

The fumbling, bumbling, balancing act... The grappling with lids and containers that so many patients go through when they try to collect a midstream urine specimen.

And the result — too often, samples contaminated by everything from unsterile surfaces to their own bodies.

Our new Asepti-Catch reduces those problems with an easy-use design so fumble-free, it's practically patient-proof.

Look how easily it works.



1. *This self-contained, recessed cap* means you can set the cap down either side up with reduced chance of contamination of sterile surfaces. This unique patented\* design also helps to reduce patient touch contamination of the sterile inner surface of the cap.

And unlike other midstream sets, there's no need for a protective cover on the cap that requires patient manipulation.

2. *An innovative handle* for ease of use is attached to a patented protective collar design that keeps the container rim recessed and clean during the entire collection procedure.


3. *The handle and protective collar* can be easily removed by simply pushing downward on the handle *after* the cap is placed on the container.

\*Patent Pending

Each Asepti-Catch comes with three cleansing towel-ettes, simple directions and a patient label already affixed to the cap.

Asepti-Catch. The untouchable one. Your patients couldn't handle anything easier.

For a free sample, just contact your American Pharmaseal representative. Or write to American Pharmaseal, Nursing Products Division, P.O. Box 1300, Glendale, CA 91209.



American Pharmaseal

# COMPARE

30  
1-MINUTE  
SOAKS IN  
SPORICIDIN\*



5  
1-MINUTE  
SOAKS IN  
CIDEX-7™

™ Surgikos, Inc.

Dip test for illustration purposes only. Aseptic technique is recommended.

## Sporicidin® does not yellow your hands.\*

### HEPATITIS

A C.D.C. study indicates that a 1:16 dilution of Sporicidin is effective against the hepatitis B virus in 10 minutes.

Abstracts of the annual meeting of The American Society for Microbiology, P. 233, March 1982 (Centers for Disease Control, Phoenix, Arizona)

### Advantages of Sporicidin diluted for disinfection:

**No gloves are necessary.** . . Doesn't stain or irritate the hands. Also, it will not "smart" the eyes or nostrils.

**Most effective.** . . The only sterilizing solution which is fully effective against the tubercle bacillus, influenza and enteroviruses when diluted 1 in 16.

**Stable.** . . A fully effective sterilant and disinfectant for 30 days after activation.

**Equipment safe.** . . Will not harm rubber or plastics. **Safe for Scopes.**

**Saves money 3 ways.** . . An 8 oz. unit makes up to 2 gallons of hospital disinfectant. It reduces disinfection costs, shipping charges, and saves up to 97% storage space.

\* Diluted 1 in 16 for disinfection. (Other glutaraldehyde products must be used full strength only.)

### Proven. . . The most effective cold sterilant and disinfectant ever registered by the E.P.A.

"Sporicidin is (a) the fastest glutaraldehyde sterilant at room temperature, and (b) the only glutaraldehyde product that can be diluted below 2% and still qualify as a hospital disinfectant."

*Infection Control, 2(1): 26-30, 1981*

"Sporicidin. . . was both more stable and more active against test spores than. . . Cidex and Cidex-7."

*Infection Control, 1(2): 90-93, 1980*

"This study has determined that although E.P.A. requirements for classifying a sterilizing agent were satisfied by Cidex, they were exceeded by Sporicidin."

*Journal of Dental Research, Vol. 60, March 1981, (U.S. Army Institute of Dental Research, Wash., DC)*



THE SPORICIDIN COMPANY

## Editorial Series

### Hepatitis B Vaccine

Richard A. Garibaldi, M.D.; Bruce H. Hamory, M.D.;  
Peter N.R. Heseltine, M.D.; and Edward J. Septimus, M.D., F.A.C.P. 371

## Original Articles

### Increasing Occurrence of Methicillin-Resistant *Staphylococcus aureus* in the United States

John M. Boyce, M.D. and William A. Causey, M.D. 377

### Quantitative Antibiogram as a Potential Tool for Epidemiological Typing

D.J. Flournoy, Ph.D. 384

### Presumed Autoclave Failure Due to False-Positive Spore Strip Tests

Inge Gurevich, R.N., M.A.; Joyce E. Holmes, M.T.; and Burke A. Cunha, M.D. 388

### Comparison of Broth and Filtration Methods for Culturing of Intravenous Fluids

Jenice N. Longfield, M.D., M.P.H.; Patricia Charache, M.D.;  
Earl L. Diamond, Ph.D.; and Timothy R. Townsend, M.D. 397

### Recommended Precautions for Patients with Legionnaires' Disease

William R. Jarvis, M.D. 401

## Departments

Letters to the Editor	359	New Products and Services	420
Information for Authors	365	Legislative News	429
Topics in Clinical Microbiology	367	Hepatitis B Vaccine Directive	430
Readers' Forum	405	Calendar of Events	435
Book Reviews	410	Index to Advertisers	436
New Developments	414		

The ideas and opinions expressed by contributing authors do not necessarily reflect those of the editors or publisher.



**Publisher:** Infection Control is published bimonthly by Charles B. Slack, Inc., 6900 Grove Road, Thorofare, New Jersey 08086. Telephones: Thorofare (609) 848-1000; New York (212) 285-9777.

**Copyright 1982:** All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

**Subscriptions:** Subscription requests should be addressed to the publisher. Annual subscription price is: Individual: One year—\$26.00; Two years—\$42.00; Three years—\$58.00. Student rates: \$13.00 per year. All subscriptions, without exception, will start with the first issue published after the order is received. Back copies are available, but must be purchased separately. Cost per individual copy is \$5.00. Foreign subscribers add \$10.00 to regular rate; foreign orders, \$6.00.

**Change of address:** Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Second-class postage is paid at Thorofare, New Jersey 08086. Publisher requests Form 3547 for address correction changes.

As of Volume 1, Number 1, INFECTION CONTROL is listed in *Index Medicus*, *Current Contents—Clinical Practice*, *Hospital Literature Index*, and *Cumulative Index to Nursing and Allied Health Literature*.

# THE PRE-OP SHOWER OF PROTECTION



Preoperative total body  
cleansing with  
HIBICLENS reduces  
postoperative  
infection by half.\*

In a comparative clinical trial, the  
superiority of HIBICLENS over  
routine cleansing procedures  
was proven.

## HIBICLENS®

(chlorhexidine gluconate)

The Only Proven Antiseptic/Antimicrobial  
Skin Cleanser



Showering or bathing  
with HIBICLENS before  
surgery minimizes  
resident flora  
from the operation  
site as well as other areas of the  
patient's body—potential  
sources of postoperative  
wound infection.

\*Brandberg A, Holm J, Hammarsten J, et al: Paper II, in *Problems in the Control of Hospital Infection, Royal Society of Medicine International Congress and Symposium Series No. 23*. London, Academic Press Inc. Ltd.

© 1980 ICI Americas Inc.



**STUART PHARMACEUTICALS** | Div. of ICI Americas Inc.  
WILMINGTON, DELAWARE 19897



# EDITORIAL BOARD

## INFECTION CONTROL

### EDITOR

Richard P. Wenzel, MD  
Charlottesville, Virginia

### SENIOR ASSOCIATE EDITOR

William Schaffner, MD  
Nashville, Tennessee

### ASSOCIATE EDITORS

Sue Crow, RN, BS, MSN  
Shreveport, Louisiana

John E. McGowan, Jr., MD  
Atlanta, Georgia

Dennis G. Maki, MD  
Madison, Wisconsin

### EDITORIAL ADVISORY BOARD

Robert C. Aber, MD  
Hershey, Pennsylvania

Charles S. Bryan, MD  
Columbia, South Carolina

John P. Burke, MD  
Salt Lake City, Utah

Richard E. Dixon, MD  
Trenton, New Jersey

Harvey A. Elder, MD  
Loma Linda, California

Peter C. Fuchs, MD, PhD  
Portland, Oregon

Richard A. Garibaldi, MD  
Farmington, Connecticut

Donald A. Goldmann, MD  
Boston, Massachusetts

Dieter H.M. Gröschel, MD  
Charlottesville, Virginia

Peter A. Gross, MD  
Hackensack, New Jersey

Karen Hadley, RN, MPH  
New Orleans, Louisiana

Cyrus C. Hopkins, MD  
Boston, Massachusetts

Allen B. Kaiser, MD  
Nashville, Tennessee

Harold Laufman, MD, PhD  
Bronx, New York

William J. Ledger, MD  
New York, New York

Barbara McArthur, RN, BSN, MS, PhD  
Detroit, Michigan

Rob Roy MacGregor, MD  
Philadelphia, Pennsylvania

C. Glen Mayhall, MD  
Richmond, Virginia

Ronald Lee Nichols, MD  
New Orleans, Louisiana

Harry C. Nottebart, Jr., JD, MD  
Richmond, Virginia

Karen Paul, BS, MS  
Tacoma, Washington

Frank S. Rhame, MD  
Minneapolis, Minnesota

William E. Scheckler, MD  
Madison, Wisconsin

Robert J. Shannon, MSPH  
Boston, Massachusetts

Walter E. Stamm, MD  
Seattle, Washington

Charles W. Stratton, MD  
Nashville, Tennessee

Timothy R. Townsend, MD  
Baltimore, Maryland

William M. Valenti, MD  
Rochester, New York

James Veazey, MD  
Albany, New York

Kathy J. Wydra, RN  
Rochester, New York

### FOREIGN ADVISORY BOARD

Graham Ayliffe, MD, FRC Path.  
Birmingham, England

Professor G. Berencsi  
Szeged, Hungary

Professor Jaap Dankert  
Groningen, Netherlands

Professor Dr. F. Daschner  
Freiburg, West Germany

Lars O. Kallings, MD  
Stockholm, Sweden

Professor W.B. Kedzia  
Sieroca, Poland

Professor A.P. Krasilnikow  
Minsk, USSR

Professor Dr. W. Marget  
Munich, West Germany

Bertil Nystrom, MD  
Huddinge, Sweden

Ian Phillips, MA, MD, MRC Path, MRCP  
London, England

Hans Reber, MD  
Basel, Switzerland

Professor Gerald Reybrouck  
Leuven, Belgium

Manfred L. Rotter, MD, DipBact  
Vienna, Austria

Theodore Sacks, MD  
Jerusalem, Israel

Professor Dr. med. H.P. Werner  
Mainz, West Germany

Professor Dr. W. Weuffen  
Griefswald, German Democratic Republic

# SLACK

Charles B. Slack, Inc.  
6900 Grove Road  
Thorofare, New Jersey 08086

**Managing Editor**  
Donna Carpenter

**Consulting Editor**  
Eric Baloff

**Associate Publisher**  
Richard N. Roash



**Assistant Editor**  
John C. Carter

**Editorial Assistants**  
Jody Zackon, *Supervisor*  
Janice Rodan

**Promotion Manager**  
Peter N. Slack

**Circulation Manager**  
Betty J. Sheldon

**Advertising Sales Representative**  
Linda Nelson



## New Power In Your Fight Against Nosocomial Infection

YES! I want to know more about BAC-DATA's infection control services. Please send me information on:

- Antibiotic Utilization Auditing (AUA)
- Infection Alert Reports (IAR)
- Bacteriologic Monitoring System (BMS)

Please have a BAC-DATA representative contact me.

Name \_\_\_\_\_

Title \_\_\_\_\_

Institution \_\_\_\_\_

Address \_\_\_\_\_

City/State/Zip \_\_\_\_\_

Phone \_\_\_\_\_

No. of Beds \_\_\_\_\_

Stop by Booth #305 at the APIC in New Orleans and register for the drawing of valuable prizes!

# BAC-DATA<sup>®</sup>

Bac-Data's new, improved Infection Control Services are a powerful supplement to your hospital's infection surveillance program.

We provide you with detailed reports which allow you to **track nosocomial trends for the most current three months**. These reports are **flexible and can be tailored to fit your reporting criteria** — service, nursing unit, diagnosis, physician, predisposing factor . . . or several additional options. If you decide to change your reports at any time, we can readily accommodate your request. **You always maintain control of the analysis of your surveillance data.**

Bac-Data's Infection Control Services:

- Provide a **series of concise reports** designed especially for infection control committee meetings.
- Show your nosocomial experience **for the past three months**. You see nosocomial trends, not just current information.
- **Simplify collection and interpretation of surveillance findings.**
- **Provide valuable documentation in the event of malpractice litigation.**
- **Help you comply with JCAH recommendations.**

Put our Infection Control Services in your corner to help win the fight against nosocomial infection. Our **NO RISK, TRIAL PROGRAM** lets you use and evaluate our services fully before making a decision to order.

Call Bac-Data now . . . collect . . . at (201) 790-6400 or send the coupon to Bac-Data Medical Information Systems, Inc., Campus Road, Totowa, N.J. 07512.